• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

A Review of Direct Oral Anticoagulants in Patients With Stage 5 or End-Stage Kidney Disease
CONCLUSIONS: If OACs for stroke prevention with AF are deemed necessary, apixaban or rivaroxaban can be considered. DOACs cannot currently be recommended over warfarin in patients with CKD-5 or ESKD and VTE.PMID:34459281 | DOI:10.1177/10600280211040093
Source: The Annals of Pharmacotherapy - August 30, 2021 Category: Drugs & Pharmacology Authors: Jessica A Starr Nathan A Pinner Melanie Mannis Mary Katherine Stuart Source Type: research

Direct Oral Anticoagulants Versus Warfarin in the Treatment of Left Ventricular Thrombus.
CONCLUSION AND RELEVANCE: Our data suggest that DOACs may be reasonable alternatives for treatment of LV thrombus. When added to the totality of available studies, this study demonstrates that the effectiveness of DOACs in LV thrombus remains uncertain. Randomized clinical trials are needed. PMID: 33191781 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - November 15, 2020 Category: Drugs & Pharmacology Authors: Willeford A, Zhu W, Stevens C, Thomas IC Tags: Ann Pharmacother Source Type: research

Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
Conclusion and Relevance: Although not statistically significant, rivaroxaban trended toward a lower incidence of clinical failure while demonstrating a significantly shorter LOS when compared with warfarin for VTE treatment or atrial fibrillation in morbidly obese or high-body-weight patients. PMID: 31672028 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - October 30, 2019 Category: Drugs & Pharmacology Authors: Perales IJ, San Agustin K, DeAngelo J, Campbell AM Tags: Ann Pharmacother Source Type: research

Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation.
Conclusion and Relevance: Apixaban and rivaroxaban may be considered as alternatives to warfarin for atrial fibrillation or flutter in morbidly obese patients. Dabigatran use in morbidly obese patients needs caution until further studies are conducted. PMID: 30130979 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - August 22, 2018 Category: Drugs & Pharmacology Authors: Kido K, Ngorsuraches S Tags: Ann Pharmacother Source Type: research

Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease.
Conclusion and Relevance: Patients with advanced CKD taking apixaban had similar bleeding rates at 3 months compared with those taking warfarin. However, those who continued therapy had higher major bleeding rates with warfarin between 6 and 12 months. This study provides knowledge on the effects of a direct oral anticoagulant in a population that was excluded from all major trials. PMID: 29871510 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - June 1, 2018 Category: Drugs & Pharmacology Authors: Schafer JH, Casey AL, Dupre KA, Staubes BA Tags: Ann Pharmacother Source Type: research

Direct Oral Anticoagulants in Cardioversion: A Review of Current Evidence.
CONCLUSIONS: DOACs may be an attractive alternative to warfarin because of fast onset of action, potentially reducing delay to cardioversion. More robust studies are needed in patients with renal dysfunction and patients undergoing pharmacological cardioversion. PMID: 29025267 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - October 1, 2017 Category: Drugs & Pharmacology Authors: Gibson CM, Basto AN, Howard ML Tags: Ann Pharmacother Source Type: research

Efficacy and Safety of Uninterrupted Low-Intensity Warfarin for Radiofrequency Catheter Ablation of Atrial Fibrillation in the Elderly: A Pilot Study.
CONCLUSIONS: Uninterrupted low-intensity warfarin for RFCA of AF might be as effective as standard-intensity warfarin in preventing periprocedural thromboembolic complications and might be associated with fewer bleeding events in the elderly. PMID: 28573932 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - June 1, 2017 Category: Drugs & Pharmacology Authors: Xing Y, Xu B, Xu C, Peng F, Yang B, Qiu Y, Sun Y, Wang S, Guo H Tags: Ann Pharmacother Source Type: research

Edoxaban, a Novel Oral Factor Xa Inhibitor.
CONCLUSIONS: Edoxaban is a safe and effective anticoagulant to reduce the risk of stroke in patients with NVAF and for the treatment of VTE. PMID: 25855704 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - April 8, 2015 Category: Drugs & Pharmacology Authors: Minor C, Tellor KB, Armbruster AL Tags: Ann Pharmacother Source Type: research

Current State of Knowledge on Oral Anticoagulant Reversal Using Procoagulant Factors(June).
CONCLUSIONS:Patients contemplating using the new oral anticoagulants should be informed about specific clinical situations that could pose a bleeding risk such as the need for emergency surgery because no reliable antidote is available to stop the bleeding, which could prove fatal. PMID: 23695644 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - May 21, 2013 Category: Drugs & Pharmacology Authors: Nitzki-George D, Wozniak I, Caprini JA Tags: Ann Pharmacother Source Type: research

Review of Economics and Cost-Effectiveness Analyses of Anticoagulant Therapy for Stroke Prevention in Atrial Fibrillation in the US.
CONCLUSIONS: This review identified several areas of uncertainty regarding the economic benefit of anticoagulants. The generalizability of cost-effectiveness results of anticoagulant therapy in AF based on clinical trial data must be confirmed by comparative effectiveness research conducted in the real-world setting. PMID: 23606551 [PubMed - in process]
Source: The Annals of Pharmacotherapy - May 1, 2013 Category: Drugs & Pharmacology Authors: von Schéele B, Fernandez M, Hogue SL, Kwong WJ Tags: Ann Pharmacother Source Type: research

Role of new drugs for management of atrial fibrillation.
CONCLUSIONS: Use of dronedarone should be limited to patients with paroxysmal or persistent AF and should not be used in patients with heart failure or with permanent AF. Newer antithrombotic agents appear to be promising alternatives for the prevention of stroke in patients with AF; however, more data are needed to understand their role. PMID: 23249869 [PubMed - in process]
Source: The Annals of Pharmacotherapy - December 1, 2012 Category: Drugs & Pharmacology Authors: Hollands JM, Gowan M, Riney JN, Deal EN, Kates AM Tags: Ann Pharmacother Source Type: research